GSK plc reported higher profit and revenues in Q4, with a fiscal 2026 outlook anticipating growth in core profit and turnover. The company expects core earnings per share and core operating profit to grow between 7% and 9% in 2026, with turnover increasing between 3% and 5%. GSK CEO Luke Miels highlighted strong performance in 2025, especially in Specialty Medicines. The company also declared an increased dividend for Q4 and full year 2025. Profit before taxation in Q4 grew to 950 million pounds, with revenue for the period increasing by 6.2% to 8.618 billion pounds.

Read more at Nasdaq: GSK Q4 Results Climb; Sees Growth In FY26, Backs 2031 Sales View – Update